StockIQpro
NYSE:TOVX

Theriva Biologics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Theriva Biologics, Inc. reported net income of −$23.7M in fiscal 2025. Free cash flow was −$16.7M, and the diluted share count rose 800.6%.Summary generated from Theriva Biologics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−329.1%
Return on equity−137.8%
Debt / equity0.11
Free cash flow−$16.7M
FCF marginn/a
Share count change+800.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−14−22−21−26−24
Net income−14−20−18−26−24
Free cash flow−13−19−19−17−17

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations